Ocankitug Biosimilar - Research Grade

Human

TSLP

>1mg/ml

IgG1 - kappa

CHO Cells

Tezepelumab Biosimilar - Research Grade (ICH5213), Bosakitug Biosimilar - Research Grade (ICH5410), Ecleralimab Biosimilar - Research Grade (ICH5499)

https://www.imgt.org/mAb-DB/

ICH3002

Q969D9

Blue ice

ICH5720 is an unconjugated, non-therapeutic recombinant analog of the anti-TSLP antibody Ocankitug, supplied strictly for research use only. It is a full-length human IgG1/kappa immunoglobulin engineered around the same molecular target as the originator drug, thymic stromal lymphopoietin (TSLP), and is not the clinical product, nor is it intended for human or veterinary use. The analog is useful as a target-specific tool for characterizing TSLP biology and antibody behavior in controlled settings: as a positive or reference control in binding and neutralization assays, as a benchmarking reagent alongside other anti-TSLP molecules, for epitope and affinity work, and as a building block in ADC or bispecific development pipelines. Material is offered at research grade with low endotoxin (typically <1 EU/mg, with an ultra-low <0.5 EU/mg option) and can be supplied in bulk quantities from milligram to gram scale, along with formats suitable for in-vitro and preclinical in-vivo standardization studies. It is provided for ichorbio review and should be described accurately as an analog built around the TSLP target rather than as the marketed therapeutic. Thymic stromal lymphopoietin (TSLP) is an IL-7-like, four-helix-bundle cytokine produced mainly by epithelial cells at barrier surfaces such as the lung, skin, and gut, typically in response to allergens, viruses, and other pro-inflammatory triggers. TSLP signals through a heterodimeric receptor comprising the TSLP receptor chain (TSLPR/CRLF2) paired with the IL-7 receptor alpha chain (IL7RA), activating downstream JAK/STAT signaling. Acting on dendritic cells, T cells, mast cells, and innate lymphoid cells, TSLP is an upstream driver of type 2 inflammation and helps orchestrate allergic and inflammatory responses. Because it sits high in the inflammatory cascade, TSLP is a validated target in respiratory and allergic disease research, and reagents that bind TSLP are widely used to probe how blocking this cytokine disrupts receptor engagement and downstream immune activation.

Thymic stromal lymphopoietin

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Ocankitug biosimilar available in bulk or gram quantities?

A: Yes — the Ocankitug biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is research-grade Ocankitug suitable for in vivo studies?

A: Yes, it is supplied as a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Ocankitug biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar monoclonal antibody analogous to Ocankitug that binds TSLP; for research use only (RUO).